COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

The authors aimed to determine the efficacy of combining mFOLFOX6/bevacizumab with atezolizumab compared to atezolizumab alone as a first-line treatment for patients with deficient DNA mismatch repair metastatic colorectal cancer (dMMR/MSI-H mCRC). The study found that the combination therapy significantly improved progression-free survival and response rates compared to atezolizumab monotherapy, suggesting a potential new standard of care for this patient population.